Locally Advanced Solid Tumor
Conditions
Keywords
antibody drug conjugate (ADC)
Brief summary
The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.
Interventions
DRUGOBI-999
For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Sponsors
OBI Pharma, Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients, 18 years of age or older at the time of consent. 2. Provide written informed consent prior to performing any study related procedure. 3. Histologically or cytologically confirmed patients with advanced solid tumors. 4. Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. In the latter case, the informed consent must state the effective therapies the patient is declining. 5. Measurable disease (i.e., at least one measurable lesion per RECIST 1.1) 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 7. Adequate organ function defined as: a. Hepatic: i. Serum ALT ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases ii. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases iii.Serum bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis) b. Renal: i. Creatinine clearance \>50 mL/minute using Cockcroft Gault equation c. Hematologic: i. Absolute neutrophil count ≥1,500/µL ii. Platelets ≥100,000/µL iii. Hemoglobin ≥8 g/dL 8. Patient is willing and able to comply with all protocol required assessments, visits, and procedures, including a pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline. 9. Females of childbearing potential must have negative serum pregnancy test prior to starting study therapy, and agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug. Patient not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause. Male patients must agree to use an adequate method of contraception during the study treatment period and for at least 120 days following the last dose of study drug. 10. Cannot be breast feeding. 11. Patients with human immunodeficiency virus (HIV) infection are eligible if CD4+ T cell counts ≥ 350 cells/uL; patients on antiretroviral therapy (ART) should be on an established dose for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment. 12. Patients with serological evidence of chronic hepatitis B virus (HBV) infection are eligible if they have an HBV viral load below the limit of quantification with or without concurrent viral suppressive therapy. 13. Patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and have a viral load below the limit of quantification. 14. Patients in Part B (Cohort-Expansion) must have documented Globo H H score of at least 100 from a qualified laboratory IHC assay in one of the sponsor-selected tumor types to be enrolled in the respective cohort: * Cohort 1: Pancreatic cancer * Cohort 2: Esophageal cancer * Cohort 3: Gastric cancer * Cohort 4: Colorectal cancer * Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1 through 4).
Exclusion criteria
1. Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks, whichever is shorter, from prior biologic therapies, prior to the first dose of OBI 999. 2. Has undergone a major surgical procedure (as defined by the Investigator) or significant traumatic injury within 28 days prior to the first dose of OBI 999. 3. Sensory or motor neuropathy of Grade 2 or greater. 4. Patients with a history of solid organ transplant. 5. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using NCI CTCAE version 5.0), except for alopecia and laboratory values listed in the inclusion criteria. 6. Receipt of any prior therapy targeting Globo H. 7. Known hypersensitivity to OBI 999 or its excipients. 8. Has known untreated central nervous system metastases. Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the screening period. 9. Has significant clinical cardiac abnormality (e.g., clinical heart failure or unstable angina) 10. Any medical co morbidity that is life threatening or, in the opinion of the Investigator, renders the patient unsuitable for participation in a clinical trial due to possible noncompliance, would place the patient at an unacceptable risk and/or potential to affect interpretation of results of the study. 11. Is receiving any concurrent prohibited medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) (CR+PR) | Every 6 weeks (±7 days) for first 3 months, then every 9 weeks (±7 days) until discontinuation of study treatment, disease progression, death, or initiation of further cancer therapy, or for up to 35 cycles (approximately 2 years.), whichever occurs first | Assessment of OBI-999 clinical benefit rate for dose escalation and cohort expansion phases of the OBI 999-001 study. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Part A, Dose Escalation - OBI-999 0.4 mg/kg OBI-999 0.4 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 3 |
| Part A, Dose Escalation - OBI-999 0.8 mg/kg OBI-999 0.8 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 3 |
| Part A, Dose Escalation - OBI-999 1.2 mg/kg OBI-999 1.2 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 6 |
| Part A, Dose Escalation - OBI-999 1.6 mg/kg OBI-999 1.6 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 3 |
| Part B, Cohort Expansion - Cohort 1, Pancreatic OBI-999 1.2 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 11 |
| Part B, Cohort Expansion - Cohort 2, Colorectal Cancer OBI-999 1.2 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 10 |
| Part B, Cohort Expansion - Cohort 3, Basket (Any Other Solid Tumor Other Than Cohorts 1 and 2) OBI-999 1.2 mg/kg was administered as an IV infusion on Day 1 of each 21-day cycle | 8 |
| Total | 44 |
Baseline characteristics
| Characteristic | Part A, Dose Escalation - OBI-999 0.4 mg/kg | Part A, Dose Escalation - OBI-999 0.8 mg/kg | Part A, Dose Escalation - OBI-999 1.2 mg/kg | Part A, Dose Escalation - OBI-999 1.6 mg/kg | Part B, Cohort Expansion - Cohort 1, Pancreatic | Part B, Cohort Expansion - Cohort 2, Colorectal Cancer | Part B, Cohort Expansion - Cohort 3, Basket (Any Other Solid Tumor Other Than Cohorts 1 and 2) | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 53.7 years STANDARD_DEVIATION 16.44 | 70.3 years STANDARD_DEVIATION 5.13 | 55.2 years STANDARD_DEVIATION 8.47 | 54.7 years STANDARD_DEVIATION 18.9 | 62.1 years STANDARD_DEVIATION 11.48 | 59.6 years STANDARD_DEVIATION 10.66 | 62.9 years STANDARD_DEVIATION 8.15 | 60.2 years STANDARD_DEVIATION 11.05 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 2 Participants | 2 Participants | 3 Participants | 11 Participants | 7 Participants | 8 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized Race (custom) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race (custom) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 4 Participants | 2 Participants | 3 Participants | 9 Participants |
| Race/Ethnicity, Customized Race (custom) Black or African American | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Race (custom) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race (custom) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race (custom) Other | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Race (custom) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Race (custom) White | 3 Participants | 2 Participants | 4 Participants | 1 Participants | 7 Participants | 5 Participants | 5 Participants | 27 Participants |
| Region of Enrollment Taiwan | 0 participants | 0 participants | 0 participants | 0 participants | 4 participants | 1 participants | 2 participants | 7 participants |
| Region of Enrollment United States | 3 participants | 3 participants | 6 participants | 3 participants | 7 participants | 9 participants | 6 participants | 37 participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 3 Participants | 2 Participants | 5 Participants | 5 Participants | 4 Participants | 20 Participants |
| Sex: Female, Male Male | 2 Participants | 3 Participants | 3 Participants | 1 Participants | 6 Participants | 5 Participants | 4 Participants | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 3 | 1 / 3 | 0 / 6 | 1 / 3 | 3 / 11 | 1 / 10 | 1 / 8 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 5 / 6 | 3 / 3 | 10 / 11 | 10 / 10 | 7 / 8 |
| serious Total, serious adverse events | 2 / 3 | 1 / 3 | 2 / 6 | 3 / 3 | 8 / 11 | 2 / 10 | 0 / 8 |
Outcome results
Primary
Objective Response Rate (ORR) (CR+PR)
Assessment of OBI-999 clinical benefit rate for dose escalation and cohort expansion phases of the OBI 999-001 study.
Time frame: Every 6 weeks (±7 days) for first 3 months, then every 9 weeks (±7 days) until discontinuation of study treatment, disease progression, death, or initiation of further cancer therapy, or for up to 35 cycles (approximately 2 years.), whichever occurs first
Population: The efficacy population consists of all patients who are enrolled, have received at least 1 dose of study drug, and had at least one follow-up tumor assessment scan.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A, Dose Escalation - OBI-999 0.4 mg/kg | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |
| Part A, Dose Escalation - OBI-999 0.8 mg/kg | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |
| Part A, Dose Escalation - OBI-999 1.2 mg/kg | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |
| Part A, Dose Escalation - OBI-999 1.6 mg/kg | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |
| Part B, Cohort Expansion - Cohort 1, Pancreatic | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |
| Part B, Cohort Expansion - Cohort 2, Colorectal Cancer | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |
| Part B, Cohort Expansion - Cohort 3, Basket (Any Other Solid Tumor Other Than Cohorts 1 and 2) | Objective Response Rate (ORR) (CR+PR) | 0 % of participants |